Source: GlobalNewswire

Press Release: Zosano Pharma : Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA

FREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company completed its Type A meeting with the U.S. Food and Drug Administration ("FDA") Division of Neurology II (the "Division") regarding the requirements for resubmission of the Qtrypta (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application ("NDA") following the Complete Response Letter received on October 20, 2020.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
$ < 1M
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating


Read more